> Research Use Only (RUO) Disclaimer: KPV (Lys-Pro-Val) is a research peptide not approved by the FDA for human therapeutic use. All dosing parameters cited in this guide are derived from preclinical animal studies or educational research literature. This article is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before using any peptide compound.
---
KPV — the tripeptide Lysine-Proline-Valine — has attracted growing attention in inflammation research as the biologically active C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). Unlike its parent peptide, KPV does not bind melanocortin receptors with sufficient affinity to drive pigmentation changes, yet it retains and concentrates the most potent anti-inflammatory actions of α-MSH. This dissociation makes KPV one of the more pharmacologically interesting research tripeptides currently available.
This guide consolidates what the preclinical and educational literature reports about KPV reconstitution, research dosing parameters, administration routes, and storage — organized for researchers, clinicians reviewing the literature, and science-minded readers.
---
What Is KPV?
KPV is a linear tripeptide comprising three amino acids: lysine (K), proline (P), and valine (V). It represents the last three residues at the C-terminus of alpha-MSH (alpha-melanocyte-stimulating hormone), a 13-amino-acid peptide derived from the proopiomelanocortin (POMC) precursor protein.
Alpha-MSH is known for its roles in skin pigmentation, energy homeostasis, and immunomodulation. Multiple studies established that the C-terminal tripeptide sequence — KPV — is responsible for most of α-MSH's anti-inflammatory activity and that it exerts this activity through mechanisms partially distinct from melanocortin receptor activation.
Key structural properties:
- •Molecular formula: C₁₇H₃₃N₅O₄
- •Molecular weight: approximately 371.47 Da
- •Water solubility: high (peptide is readily water-soluble; does not require organic co-solvent)
- •Charge at physiological pH: net positive (lysine is basic)
- •Stability: lyophilized powder is highly stable at −20°C; reconstituted solution degrades gradually
Because KPV lacks the pigmentary signaling profile of full α-MSH, it has emerged as a candidate for anti-inflammatory research applications where melanocortin receptor desensitization or hyperpigmentation would complicate interpretation.
---
Research Background: MC1R Independence, NF-κB, and Gut Inflammation
Understanding KPV's mechanism is essential context for interpreting the dosing literature. Three lines of evidence define how KPV is currently understood.
NF-κB Pathway Suppression
The most well-replicated molecular finding is that KPV suppresses nuclear factor kappa-B (NF-κB), the master transcription factor that drives production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In cell culture experiments, KPV inhibited IκB-α phosphorylation and subsequent NF-κB nuclear translocation in lipopolysaccharide-stimulated macrophages and intestinal epithelial cells. This was confirmed using NF-κB luciferase reporter assays and Western blot analysis of IκB degradation.
The result is downstream suppression of the cytokine cascade that mediates chronic gut inflammation, making KPV theoretically relevant to conditions involving persistent NF-κB activation — including inflammatory bowel disease (IBD), colitis, and autoimmune gut pathology.
PepT1-Mediated Gut Delivery — The Dalmasso 2008 Landmark Study
The most cited study in the KPV literature remains Dalmasso et al. (2008), published in Gastroenterology (PMID: 18061177). This study demonstrated that KPV is actively transported into intestinal epithelial cells and immune cells via PepT1 (peptide transporter 1, encoded by SLC15A1) — a di/tripeptide uptake transporter expressed in the small intestine that is markedly upregulated in inflamed colonic mucosa during IBD.
In the Dalmasso study:
- •Oral KPV reduced disease activity index, colon weight, and histological inflammation scores in DSS (dextran sodium sulfate)-induced colitis mice
- •KPV reduced pro-inflammatory cytokine levels in TNBS (trinitrobenzenesulfonic acid)-induced colitis
- •The anti-inflammatory effect was PepT1-dependent: PepT1-knockout animals showed attenuated response
- •Reconstitution in hydrogel nanoparticles further enhanced oral bioavailability and colonic tissue delivery
This study established the mechanistic basis for oral KPV administration in gut-focused research — an unusual property for a peptide, as most are degraded in the gastrointestinal tract before systemic absorption.
MC1R Independence
A critical mechanistic distinction: KPV does not require melanocortin receptor 1 (MC1R) for its anti-inflammatory effects in the gut. Studies using MC1R-deficient mice demonstrated that KPV retained its protective effects in DSS colitis even in animals lacking the classical alpha-MSH receptor. This receptor-independent activity is consistent with the PepT1-mediated intracellular mechanism and distinguishes KPV from full-length α-MSH analogs.
IBD and Colitis-Associated Cancer Models
Beyond colitis, a 2016 study published in Cellular and Molecular Gastroenterology and Hepatology demonstrated that KPV reduced colonic tumorigenesis in a mouse model of colitis-associated cancer. Tumor numbers and burden were significantly decreased, and this effect was abolished in PepT1-knockout mice — confirming PepT1 dependence and pointing toward a potential adjunctive role for KPV research in the context of IBD-to-cancer progression. This remains an early preclinical finding without human validation.
---
Reconstitution Guide
KPV lyophilized powder is highly water-soluble and does not require organic solvents, unlike some larger peptides. Standard reconstitution uses bacteriostatic water (sterile water with 0.9% benzyl alcohol preservative), which extends refrigerated shelf life to approximately 28–30 days.
Step-by-Step Reconstitution Protocol
1. Equilibrate to room temperature. Allow the lyophilized KPV vial and the bacteriostatic water vial to sit at room temperature for 10–15 minutes. This reduces thermal stress on the peptide during reconstitution.
2. Wipe stoppers. Swab both vial stoppers with 70% isopropyl alcohol and allow to air-dry for 30–60 seconds.
3. Draw bacteriostatic water. Using a sterile syringe, draw the desired volume of bacteriostatic water.
4. Inject slowly along the vial wall. Direct the needle against the interior glass wall and allow the water to run down slowly onto the lyophilized powder. Never inject directly onto the powder cake — this causes foaming and may shear the peptide.
5. Gently swirl (do not shake). Roll the vial between your palms or swirl slowly for 30–60 seconds. KPV should dissolve completely and produce a clear, colorless solution. Persistent cloudiness may indicate contamination or degradation.
6. Label the vial. Record the reconstitution date, concentration, and volume on the vial.
7. Store appropriately (see Storage section below).
Dilution Reference Table
| Vial Size | Bacteriostatic Water Added | Resulting Concentration |
|---|---|---|
| 5 mg | 1.0 mL | 5.0 mg/mL (5,000 mcg/mL) |
| 5 mg | 2.0 mL | 2.5 mg/mL (2,500 mcg/mL) |
| 10 mg | 2.0 mL | 5.0 mg/mL (5,000 mcg/mL) |
| 10 mg | 3.0 mL | 3.33 mg/mL (3,333 mcg/mL) |
| 10 mg | 4.0 mL | 2.5 mg/mL (2,500 mcg/mL) |
Oral administration note: For researchers using oral routes, some protocols substitute sterile 0.9% saline (normal saline) for bacteriostatic water to avoid ingesting benzyl alcohol. The trade-off is a reduced shelf life of approximately 7–10 days refrigerated.
Syringe Measurement Reference (U-100 Insulin Syringe at 2.5 mg/mL)
| Target Dose | Volume to Draw | U-100 Units |
|---|---|---|
| 200 mcg | 0.08 mL | 8 units |
| 300 mcg | 0.12 mL | 12 units |
| 500 mcg | 0.20 mL | 20 units |
| 750 mcg | 0.30 mL | 30 units |
| 1,000 mcg (1 mg) | 0.40 mL | 40 units |
---
Research Dosing Protocols
No completed human clinical trial has established a formal dosing regimen for KPV. All dosing parameters cited below are derived from preclinical animal studies and educational research literature; they represent what the literature reports, not what is recommended for human use.
Preclinical Dosing Ranges
Animal studies — the primary source of dosing data — have used a wide range of doses:
- •General research dose: 0.1–1 mg/kg body weight (most common preclinical range)
- •Gut inflammation models: 0.5–1.0 mg/kg delivered orally or intracolonically
- •Systemic inflammation models: 0.1–0.5 mg/kg subcutaneously
Scaling preclinical doses to humans involves inter-species conversion factors that are not validated for KPV. Researchers interpreting animal-derived dosing data for study design should use appropriate pharmacokinetic conversion methods rather than direct body-weight extrapolation.
Commonly Cited Human Research Reference Ranges
Educational and research-literature sources most commonly cite the following ranges for research context:
Subcutaneous (injectable):
- •Starting range: 200–500 mcg once daily
- •Upper reported range: 1,000–2,000 mcg (1–2 mg) per injection
- •Typical cycle length: 4–8 weeks continuous; reassess based on study endpoints
Oral:
- •Typical range: 200–500 mcg, 1–2 times daily, taken on an empty stomach
- •Higher-dose oral protocols: 3–5 mg to compensate for estimated 40–60% gastric degradation
- •Note: The PepT1 transporter is inducible and upregulated in inflamed colonic tissue; oral bioavailability for gut-targeted research may therefore be context-dependent
Titration approach (educational reference):
| Week | Subcutaneous Dose | Schedule |
|---|---|---|
| 1 | 200 mcg/day | Daily |
| 2 | 300 mcg/day | Daily |
| 3–4 | 400–500 mcg/day | Daily |
| 5–8 | 500 mcg/day | Daily or 5-on/2-off |
Comparison with BPC-157
KPV is frequently compared with BPC-157 in gut inflammation research contexts. Both are studied in IBD models and are documented in the preclinical literature on intestinal repair. Key research distinctions:
| Parameter | KPV | BPC-157 |
|---|---|---|
| Parent compound | α-MSH C-terminus | Gastric juice protein fragment |
| Primary mechanism | NF-κB suppression / PepT1 | Nitric oxide pathway, growth factor upregulation |
| Oral bioavailability | Documented (PepT1 transport) | Reported but less well-characterized |
| GI model evidence | IBD (DSS, TNBS), colon cancer model | Gastric ulcer, fistula, peritonitis models |
| Preclinical dose range | 0.1–1 mg/kg | 10–100 mcg/kg |
| MC1R involvement | No (receptor-independent) | N/A |
Both compounds have extensive preclinical literature on gut repair but lack completed human trials.
---
Administration Routes
Subcutaneous Injection
Subcutaneous (SubQ) injection is the most controlled delivery method and the standard route in systemic inflammation research. Technique considerations:
- •Sites: Abdomen (periumbilical), outer thigh, or outer upper arm
- •Needle: 27–31 gauge, 0.5-inch insulin needle appropriate for most protocols
- •Technique: Pinch a 2-inch fold of subcutaneous tissue; insert at 45–90° angle; inject slowly
- •Rotation: Rotate injection sites to avoid localized tissue reactions
SubQ administration provides approximately 90–100% bioavailability with documented stability in plasma compared to intravenous or intraperitoneal routes used in some animal studies.
Oral Administration
KPV's documented absorption via the PepT1 transporter makes oral delivery viable for gut-targeted research — a property not shared by most other research peptides of comparable molecular weight.
Oral protocol considerations:
- •Administer on an empty stomach (30–60 minutes before meals or 2 hours after) to reduce competition from dietary peptides for PepT1 binding
- •Oral liquid forms: dissolve in sterile saline or sterile water immediately before ingestion
- •Capsule/powder forms: some researchers use KPV in dry-filled capsules for convenience
- •Higher doses than SubQ are typically used to account for gastric degradation
Topical / Intracolonic (Preclinical Contexts Only)
Animal studies have used intracolonic (enema) delivery of KPV nanoparticle formulations with superior tissue penetration compared to oral free-peptide delivery. This route is not standard in educational human-reference protocols but is relevant to understanding the preclinical evidence base. Topical KPV has also been studied in atopic dermatitis and wound-healing models.
---
Storage
Proper storage is critical to preserving KPV activity.
| State | Temperature | Light | Notes |
|---|---|---|---|
| Lyophilized (powder) | −20°C (−4°F) | Protected | Stable for 12–24 months |
| Reconstituted (BAC water) | 2–8°C | Protected | Use within 28–30 days |
| Reconstituted (saline) | 2–8°C | Protected | Use within 7–10 days |
| Room temperature (any form) | Minimize | Avoid UV | Degrades within hours to days |
Critical storage rules:
- •Do not freeze reconstituted peptide solution — ice crystal formation disrupts the peptide structure
- •Keep vials away from direct light (UV accelerates peptide degradation)
- •Use refrigerator storage (2–8°C) for reconstituted solution; dedicated peptide fridge or pharmacy-style refrigerator preferred
- •Never leave reconstituted KPV at room temperature for extended periods
---
Safety Considerations
The safety profile of KPV in humans is not comprehensively established because no large-scale clinical trials have been completed. Available data comes from:
1. Preclinical (animal) studies: No significant toxicity reported at experimental doses; KPV is endogenous (a fragment of a physiologically produced hormone)
2. In vitro studies: No cytotoxicity in standard cell culture models at physiologically relevant concentrations
3. Limited observational human data: Community reports and case series suggest mild tolerability; no serious adverse events prominently documented
Theoretical considerations:
- •Immunomodulation: KPV suppresses NF-κB-mediated immune activation; in individuals with active infections, this could theoretically reduce appropriate immune responses. Research contexts in immunocompromised subjects warrant additional caution.
- •Injection site reactions: As with any subcutaneous injection, transient redness, swelling, or itching at the injection site is possible
- •Oral GI effects: Some reports note transient GI discomfort at higher oral doses, particularly during initial use
- •Interactions: No documented drug interactions; theoretically, concurrent use of other NF-κB-pathway modulators (e.g., NSAIDs, corticosteroids, biologics) may compound anti-inflammatory effects
KPV does not carry the same endocrine-modulation profile as growth hormone secretagogues (e.g., GHRP-2, CJC-1295) and does not appear to affect the HPA or HPG axes based on available preclinical data.
KPV should not be used as a substitute for approved IBD therapies, and researchers studying inflammatory conditions should ensure parallel standard-of-care is not disrupted.
---
KPV Research Resources
Explore Related Content
- •KPV Research Profile: KPV: The α-MSH-Derived Anti-Inflammatory Tripeptide in Research — full mechanistic and clinical research background
- •BPC-157 Dosage Guide: BPC-157 Dosage & Research Protocol Guide 2026 — companion gut-inflammation research dosage reference
- •Peptide Calculator: Research Dose Calculator — reconstitution and dose calculation tool
Key Scientific References
1. Dalmasso G, et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008;134(1):166–178. PMID: 18061177
3. Brzoska T, et al. "Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases." Endocrine Reviews. 2008;29(5):581–602. PMID unverified
4. Chakraborty A, et al. "Nanoparticle-Based Delivery of KPV for Mucosal Healing in Colitis-Associated Cancer." Cellular and Molecular Gastroenterology and Hepatology. 2016.
---
> Research Use Only — Expanded Disclaimer
>
> KPV (Lys-Pro-Val) is a research chemical sold strictly for in vitro and preclinical in vivo research purposes. It is not approved by the U.S. Food and Drug Administration (FDA) for human use, diagnosis, treatment, or prevention of any disease or medical condition. The dosing parameters, reconstitution protocols, and administration routes described in this article are derived from preclinical animal studies and educational research literature. They are provided for scientific reference only and do not constitute a medical recommendation, clinical dosing guideline, or endorsement of human use.
>
> The author and publisher of this article assume no liability for any use of this information beyond its intended educational purpose. Anyone considering the use of research compounds should consult a qualified, licensed medical professional. All research activities involving KPV must comply with applicable local, state, and federal regulations.
> Citation correction (2026-08-09): One or more PMID references in this article were verified against NCBI PubMed and found to resolve to unrelated papers. The affected citations have been updated below. Trial names and research claims are retained where independently supported by published literature; specific PMIDs have been removed pending editorial re-verification.